J&J to Build $1B+ Cell Therapy Plant in Pennsylvania

Pharmaceutical giant expands U.S. footprint with major investment.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

Johnson & Johnson (JNJ) announced plans to construct a new cell therapy manufacturing facility in Montgomery, Pennsylvania, with an investment of over $1 billion. The facility is part of the company's broader $55 billion U.S. expansion strategy through 2029.

Why it matters

J&J's investment in a new state-of-the-art cell therapy plant signals the company's commitment to growing its pharmaceutical business and advancing innovative treatments. The facility will create hundreds of new jobs in the region and solidify Pennsylvania's reputation as a hub for the life sciences industry.

The details

The new cell therapy plant will be built in Montgomery, Pennsylvania, expanding J&J's existing footprint in the state. The over $1 billion investment is part of the company's broader $55 billion U.S. expansion plan through 2029, which includes investments in manufacturing, R&D, and other infrastructure.

  • J&J announced the new facility plans on February 18, 2026.

The players

Johnson & Johnson (JNJ)

A multinational pharmaceutical and consumer goods company headquartered in New Jersey.

Got photos? Submit your photos here. ›

What’s next

The new cell therapy plant is expected to begin operations in the next 3-5 years, creating hundreds of new jobs in the Montgomery, PA region.

The takeaway

J&J's major investment in a new state-of-the-art cell therapy facility underscores the company's commitment to growing its pharmaceutical business and advancing innovative treatments. The project will also boost the local economy and solidify Pennsylvania's reputation as a hub for the life sciences industry.